Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study

Vincenzo Mirone, Roberta d'Emmanuele di Villa Bianca, Emma Mitidieri, Ciro Imbimbo, Ferdinando Fusco, Paolo Verze, Dino F. Vitale, Raffaella Sorrentino, Giuseppe Cirino

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Phosphodiesterase 5 inhibitors (PDE5-Is) are a mainstay in the therapy of erectile dysfunction (ED). The primary end point of clinical efficacy, both in clinical studies and normal practice, is represented by the International Index of Erectile Function (IIEF). Objective: To evaluate if platelet cyclic guanosine monophosphate (cGMP) could represent a valuable marker for PDE5-I activity in ED. Design, setting, and participants: The study enrolled 46 patients with psychogenic, organic, and mixed ED (20-71 yr of age; IIEF score

Original languageEnglish
Pages (from-to)1067-1073
Number of pages7
JournalEuropean Urology
Volume56
Issue number6
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Phosphodiesterase 5 Inhibitors
Cyclic GMP
Erectile Dysfunction
Blood Platelets
Biomarkers
Placebos
Therapeutics

Keywords

  • cGMP
  • Erectile dysfunction
  • Platelet
  • Vardenafil
  • VASP

ASJC Scopus subject areas

  • Urology

Cite this

Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction : A Randomized Placebo-Controlled Study. / Mirone, Vincenzo; d'Emmanuele di Villa Bianca, Roberta; Mitidieri, Emma; Imbimbo, Ciro; Fusco, Ferdinando; Verze, Paolo; Vitale, Dino F.; Sorrentino, Raffaella; Cirino, Giuseppe.

In: European Urology, Vol. 56, No. 6, 12.2009, p. 1067-1073.

Research output: Contribution to journalArticle

Mirone, V, d'Emmanuele di Villa Bianca, R, Mitidieri, E, Imbimbo, C, Fusco, F, Verze, P, Vitale, DF, Sorrentino, R & Cirino, G 2009, 'Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study', European Urology, vol. 56, no. 6, pp. 1067-1073. https://doi.org/10.1016/j.eururo.2009.09.031
Mirone, Vincenzo ; d'Emmanuele di Villa Bianca, Roberta ; Mitidieri, Emma ; Imbimbo, Ciro ; Fusco, Ferdinando ; Verze, Paolo ; Vitale, Dino F. ; Sorrentino, Raffaella ; Cirino, Giuseppe. / Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction : A Randomized Placebo-Controlled Study. In: European Urology. 2009 ; Vol. 56, No. 6. pp. 1067-1073.
@article{6361dbfdcb0d44a6b7aaeefa3ed0ddf3,
title = "Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study",
abstract = "Background: Phosphodiesterase 5 inhibitors (PDE5-Is) are a mainstay in the therapy of erectile dysfunction (ED). The primary end point of clinical efficacy, both in clinical studies and normal practice, is represented by the International Index of Erectile Function (IIEF). Objective: To evaluate if platelet cyclic guanosine monophosphate (cGMP) could represent a valuable marker for PDE5-I activity in ED. Design, setting, and participants: The study enrolled 46 patients with psychogenic, organic, and mixed ED (20-71 yr of age; IIEF score",
keywords = "cGMP, Erectile dysfunction, Platelet, Vardenafil, VASP",
author = "Vincenzo Mirone and {d'Emmanuele di Villa Bianca}, Roberta and Emma Mitidieri and Ciro Imbimbo and Ferdinando Fusco and Paolo Verze and Vitale, {Dino F.} and Raffaella Sorrentino and Giuseppe Cirino",
year = "2009",
month = "12",
doi = "10.1016/j.eururo.2009.09.031",
language = "English",
volume = "56",
pages = "1067--1073",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "6",

}

TY - JOUR

T1 - Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction

T2 - A Randomized Placebo-Controlled Study

AU - Mirone, Vincenzo

AU - d'Emmanuele di Villa Bianca, Roberta

AU - Mitidieri, Emma

AU - Imbimbo, Ciro

AU - Fusco, Ferdinando

AU - Verze, Paolo

AU - Vitale, Dino F.

AU - Sorrentino, Raffaella

AU - Cirino, Giuseppe

PY - 2009/12

Y1 - 2009/12

N2 - Background: Phosphodiesterase 5 inhibitors (PDE5-Is) are a mainstay in the therapy of erectile dysfunction (ED). The primary end point of clinical efficacy, both in clinical studies and normal practice, is represented by the International Index of Erectile Function (IIEF). Objective: To evaluate if platelet cyclic guanosine monophosphate (cGMP) could represent a valuable marker for PDE5-I activity in ED. Design, setting, and participants: The study enrolled 46 patients with psychogenic, organic, and mixed ED (20-71 yr of age; IIEF score

AB - Background: Phosphodiesterase 5 inhibitors (PDE5-Is) are a mainstay in the therapy of erectile dysfunction (ED). The primary end point of clinical efficacy, both in clinical studies and normal practice, is represented by the International Index of Erectile Function (IIEF). Objective: To evaluate if platelet cyclic guanosine monophosphate (cGMP) could represent a valuable marker for PDE5-I activity in ED. Design, setting, and participants: The study enrolled 46 patients with psychogenic, organic, and mixed ED (20-71 yr of age; IIEF score

KW - cGMP

KW - Erectile dysfunction

KW - Platelet

KW - Vardenafil

KW - VASP

UR - http://www.scopus.com/inward/record.url?scp=70350571170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350571170&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2009.09.031

DO - 10.1016/j.eururo.2009.09.031

M3 - Article

C2 - 19781847

AN - SCOPUS:70350571170

VL - 56

SP - 1067

EP - 1073

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -